Articles - Page 50 of 69 - Drugs in Context

Advances in the use of PARP inhibitor therapy for breast cancer

Kelly E McCann MD, PhD, Sara A Hurvitz MD

Article Type

Review

Published

08 Aug 2018

In the care of oncology patients, poly-ADP-ribose polymerase (PARP) inhibitors are best known as a semitargeted treatment
for BRCA1- and BRCA2-associated ovarian and breast cancers, this article reviews the broader understanding of PARP biology that has spurred interest in expanding their clinical utility.

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment

Sarah L Anderson PharmD, Joel C Marrs PharmD

Article Type

Review

Published

08 Aug 2018

This review examines sacubitril/valsartan, which has demonstrated safety and efficacy when it comes to blood pressure lowering, making it a promising antihypertensive agent.

Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors

Daniel I G Cubero MD, PhD, Beatrice Martinez Zugaib Abdalla MD, Jean Schoueri, Fabio Iazetti Lopes, Karine Corcione Turke, Jose Guzman MD, Auro Del Giglio MD, PhD, Carlos D’Apparecida Santos Machado Filho MD, PhD, Vanessa Salzano MD, Dolores Gonzalez Fabra MD

Article Type

Review

Published

17 Jul 2018

This article reviews the cutaneous side effects of main molecularly targeted cancer therapies for solid tumors.

Febrile seizures: an overview

Alexander KC Leung MBBS, FRCPC, FRCP (UK and Irel), FRCPCH, FAAP, Kam Lun Hon MD, FAAP, FCCM, Theresa NH Leung MBBS, FRCPCH, FHKAM (Paed)

Article Type

Review

Published

16 Jul 2018

This review provides an update on the current understanding, evaluation, and management of febrile seizures.

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

Alfredo Addeo MD, Giulio Metro MD

Article Type

Editorial

Published

10 Jul 2018

This editorial describes the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.